Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

10089	Companies
206337	Keywords
136518	Articles
109369	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 06/11/2025 at 16:00, 9 months 13 days ago

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Jaguar Health, Inc. announces goals to expand crofelemer usage from chemotherapy-induced to general diarrhea treatment in dogs. Research studies and partnerships in progress

Crofelemer Jaguar Health Partnerships Dogs Diarrhea Treatment
BRIEF

published on 06/09/2025 at 22:20, 9 months 15 days ago

Jaguar Health to Discuss Phase 3 Trial Results in Virtual Chat

Jaguar Health Phase 3 Trial Breast Cancer Orphan Diseases FDA Meeting
BRIEF

published on 06/09/2025 at 22:20, 9 months 15 days ago

Jaguar Health discutera des résultats de l'essai de phase 3 lors d'une discussion virtuelle

Jaguar Health Essai De Phase 3 Cancer Du Sein Maladies Orphelines Réunion De La FDA
PRESS RELEASE

published on 06/09/2025 at 22:15, 9 months 15 days ago

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series
Jaguar Health, Inc. to discuss Phase 3 OnTarget trial results for metastatic breast cancer subgroup. Focus on orphan population and expanded access program. Virtual fireside chat with CEO Lisa Conte on June 10, 2025

Jaguar Health Phase 3 OnTarget Trial Virtual Fireside Chat Metastatic Breast Cancer Orphan Population
BRIEF

published on 06/09/2025 at 15:05, 9 months 15 days ago

Jaguar Health discute du protocole Crofelemer avec la FDA

Crofelemer Désignation De Médicament Orphelin Approbation De La FDA Cancer Du Sein Métastatique Programme D'accès Élargi
BRIEF

published on 06/09/2025 at 15:05, 9 months 15 days ago

Jaguar Health Discusses Crofelemer Pathway with FDA

Crofelemer FDA Approval Orphan Drug Designation Metastatic Breast Cancer Expanded Access Program
PRESS RELEASE

published on 06/09/2025 at 15:00, 9 months 15 days ago

Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer
Jaguar Health's Napo Pharmaceuticals shares plans to seek approval for crofelemer in cancer therapy-related diarrhea for metastatic breast cancer patients. Key discussions with FDA highlighted in Type C Meeting

Napo Pharmaceuticals Crofelemer Jaguar Health Cancer Therapy Metastatic Breast Cancer
BRIEF

published on 06/06/2025 at 15:05, 9 months 18 days ago

Jaguar Health to Discuss Orphan Disease Efforts in Upcoming Fireside Chat

Napo Pharmaceuticals Crofelemer Jaguar Health Fireside Chat Orphan Disease
BRIEF

published on 06/06/2025 at 15:05, 9 months 18 days ago

Jaguar Health discutera de ses efforts en matière de maladies orphelines lors d'une prochaine discussion informelle.

Napo Pharmaceuticals Crofelemer Jaguar Health Discussion Au Coin Du Feu Maladie Orpheline
PRESS RELEASE

published on 06/06/2025 at 15:00, 9 months 18 days ago

Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners’ Spring 2025 Spotlight Series
Jaguar Health's CEO Lisa Conte will participate in a virtual fireside chat on June 10, 2025 to discuss the company's orphan disease development programs

Pharmaceuticals Jaguar Health Lisa Conte Virtual Fireside Chat Orphan Disease Development

Accesswire

Published on 03/25/2026 at 12:55, 11 minutes ago

EonX Technologies Reports FY2025 Record Revenue Growth and First Full-Year Profit
Published on 03/25/2026 at 12:30, 36 minutes ago

Gold Basin Announces Termination of Charles Straw for Cause
Published on 03/25/2026 at 12:00, 1 hour 6 minutes ago

AIML Subsidiary NeuralCloud Enters Research Services Agreement with Baker Heart and Diabetes Institute to Support AI-Driven ECG Analysis
Published on 03/25/2026 at 08:01, 5 hours 5 minutes ago

Apex Critical Metals Appoints Zayn Kalyan to Board of Directors
Published on 03/25/2026 at 04:50, 8 hours 16 minutes ago

Arctic Fox Announces Closing of First Tranche of Non-Brokered Private Placement

View all ACCESSWIRE

EQS Group

Published on 03/25/2026 at 12:55, 11 minutes ago

EQS-Adhoc: Kontron AG: Kontron AG resolves on a new Share Buyback Program I 2026 for own shares
Published on 03/25/2026 at 12:50, 16 minutes ago

Prodigy Technovations Enhances Industry leading I3C Protocol Exerciser and Analyzer with Advanced Application-Level Protocol NVMe-MI, SPDM and PLDM Support
Published on 03/25/2026 at 12:05, 1 hour 1 minute ago

Global Mobility Call 2026: The Global Benchmark for the Future of Mobility
Published on 03/25/2026 at 12:05, 1 hour 1 minute ago

Fractus and Verizon settle patent litigation
Published on 03/25/2026 at 11:10, 1 hour 56 minutes ago

MGI Tech Brings High-Throughput T7+ Sequencer to European Market at Analytica 2026 Debut

Les Echos

Published on 03/25/2026 at 08:45, 4 hours 21 minutes ago

Air Liquide inaugurates its first Advanced Materials manufacturing plant in Taiwan, strengthening the next-gen semiconductor supply chain
Published on 03/25/2026 at 08:45, 4 hours 21 minutes ago

Air Liquide inaugure sa première usine de production de Matériaux Avancés à Taïwan, renforçant ainsi la chaîne d'approvisionnement en semi-conducteurs de nouvelle génération
Published on 03/25/2026 at 07:00, 6 hours 6 minutes ago

TINC invests in large-scale battery storage to strengthen the flexibility of the Belgian electricity network (B)
Published on 03/25/2026 at 07:00, 6 hours 6 minutes ago

TINC investeert in grootschalige batterijopslag ter versterking van de flexibiliteit van het Belgische stroomnetwerk (B)
Published on 03/25/2026 at 07:00, 6 hours 6 minutes ago

TINC invests in large-scale battery storage to strengthen the flexibility of the Belgian electricity network (B)

View all LES ECHOS COMFI WIRE